| Latisse Monique Mays-stovall, MD | |
|
201 Lyons Ave, Newark, NJ 07112-2027 | |
| (973) 865-8553 | |
| (973) 282-0562 |
| Full Name | Latisse Monique Mays-stovall |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 21 Years |
| Location | 201 Lyons Ave, Newark, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134305667 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 25MA08262500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Clara Maass Medical Center | Belleville, NJ | Hospital |
| Overlook Medical Center | Summit, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Union Emergency Medical Associates Llc | 0547334427 | 17 |
| Rwjbh Observation Associates Llc | 5193137503 | 598 |
News Archive
Fatty acids are important components of cell membranes. They have signalling functions within the cells and play a role in controlling metabolic processes in the entire body. Thomas Ruf and Walter Arnold of the Research Institute of Wildlife Ecology at the University of Veterinary Medicine, Vienna, investigated these cyclic fluctuations in human cells.
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
› Verified 2 days ago
| Entity Name | Emergency Physician Associates Of North Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497783419 PECOS PAC ID: 7911992326 Enrollment ID: O20040825001558 |
News Archive
Fatty acids are important components of cell membranes. They have signalling functions within the cells and play a role in controlling metabolic processes in the entire body. Thomas Ruf and Walter Arnold of the Research Institute of Wildlife Ecology at the University of Veterinary Medicine, Vienna, investigated these cyclic fluctuations in human cells.
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
› Verified 2 days ago
| Entity Name | Union Emergency Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689847352 PECOS PAC ID: 0547334427 Enrollment ID: O20080812000013 |
News Archive
Fatty acids are important components of cell membranes. They have signalling functions within the cells and play a role in controlling metabolic processes in the entire body. Thomas Ruf and Walter Arnold of the Research Institute of Wildlife Ecology at the University of Veterinary Medicine, Vienna, investigated these cyclic fluctuations in human cells.
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
› Verified 2 days ago
| Entity Name | Rwjbh Observation Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760095806 PECOS PAC ID: 5193137503 Enrollment ID: O20201209000008 |
News Archive
Fatty acids are important components of cell membranes. They have signalling functions within the cells and play a role in controlling metabolic processes in the entire body. Thomas Ruf and Walter Arnold of the Research Institute of Wildlife Ecology at the University of Veterinary Medicine, Vienna, investigated these cyclic fluctuations in human cells.
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
› Verified 2 days ago
| Entity Name | Rwjbh Emergency Medicine Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912510041 PECOS PAC ID: 0941612840 Enrollment ID: O20201217002547 |
News Archive
Fatty acids are important components of cell membranes. They have signalling functions within the cells and play a role in controlling metabolic processes in the entire body. Thomas Ruf and Walter Arnold of the Research Institute of Wildlife Ecology at the University of Veterinary Medicine, Vienna, investigated these cyclic fluctuations in human cells.
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Latisse Monique Mays-stovall, MD 168 Marion Dr, West Orange, NJ 07052-3315 Ph: (973) 865-8553 | Latisse Monique Mays-stovall, MD 201 Lyons Ave, Newark, NJ 07112-2027 Ph: (973) 865-8553 |
News Archive
Fatty acids are important components of cell membranes. They have signalling functions within the cells and play a role in controlling metabolic processes in the entire body. Thomas Ruf and Walter Arnold of the Research Institute of Wildlife Ecology at the University of Veterinary Medicine, Vienna, investigated these cyclic fluctuations in human cells.
BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.
A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.
› Verified 2 days ago
Dr. Charles Fleischner, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Bergen St, Admc 1110, Newark, NJ 07107 Phone: 973-972-9261 | |
Allen Judah Srulowitz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 268 Dr Martin Luther King Jr Blvd, Newark, NJ 07102 Phone: 973-877-5500 | |
Dr. Christopher Delmaestro, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 201 Lyons Ave, Newark, NJ 07112 Phone: 973-926-6671 | |
Albert David Della Fave, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 150 Bergen St, Rutgers University Hospital Emergency Dept., Newark, NJ 07103 Phone: 973-972-5123 | |
Brian Joseph Kenny, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 150 Bergen St, Newark, NJ 07103 Phone: 862-241-5729 | |
Dr. Pidok Thepmankorn, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 495 N 13th St, Newark, NJ 07107 Phone: 973-268-1400 | |
Dr. Purabi Simon, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 495 North 13th Street, Newark, NJ 07107 Phone: 973-268-1400 |